BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Calvet X, Gomollón F. What is potent acid inhibition, and how can it be achieved? Drugs. 2005;65 Suppl 1:13-23. [PMID: 16335854 DOI: 10.2165/00003495-200565001-00004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Xu H, O'Gorman M, Matschke K, Boutros T, Brega N, Tan W, Bello A. Evaluation of Proton Pump Inhibitor Esomeprazole on Crizotinib Pharmacokinetics in Healthy Participants. Clin Pharmacol Drug Dev 2021. [PMID: 34825782 DOI: 10.1002/cpdd.1032] [Reference Citation Analysis]
2 Nishida T, Tsujii M, Tanimura H, Tsutsui S, Tsuji S, Takeda A, Inoue A, Fukui H, Yoshio T, Kishida O, Ogawa H, Oshita M, Kobayashi I, Zushi S, Ichiba M, Uenoyama N, Yasunaga Y, Ishihara R, Yura M, Komori M, Egawa S, Iijima H, Takehara T. Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan. World J Gastroenterol 2014; 20(15): 4362-4369 [PMID: 24764674 DOI: 10.3748/wjg.v20.i15.4362] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
3 Okimoto T, Mizukami K, Ogawa R, Okamoto K, Shuto M, Fukuda K, Kodama M, Murakami K. Esomeprazole- or rabeprazole-based triple therapy eradicated Helicobacter pylori comparably regardless of clarithromycin susceptibility and CYP2C19 genotypes. J Clin Biochem Nutr 2016;59:149-53. [PMID: 27698544 DOI: 10.3164/jcbn.16-18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Auernhammer CJ, Göke B. Medical treatment of gastrinomas. Wien Klin Wochenschr 2007;119:609-15. [PMID: 17985097 DOI: 10.1007/s00508-007-0877-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
5 Sakurai K, Suda H, Ido Y, Takeichi T, Okuda A, Hasuda K, Hattori M. Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy. World J Gastroenterol 2017; 23(4): 668-675 [PMID: 28216974 DOI: 10.3748/wjg.v23.i4.668] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
6 Okubo H, Akiyama J, Kobayakawa M, Kawazoe M, Mishima S, Takasaki Y, Nagata N, Shimada T, Yokoi C, Komori S, Kimura K, Hisada Y, Iwata E, Watanabe K, Yanagisawa N, Shiroma S, Shimomura A, Okahara K, Cho H, Uemura N. Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility. J Gastroenterol 2020;55:1054-61. [PMID: 32930864 DOI: 10.1007/s00535-020-01723-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Gravina AG, Priadko K, Granata L, Facchiano A, Scidà G, Cerbone R, Ciamarra P, Romano M. Single Capsule Bismuth Quadruple Therapy for Eradication of H. pylori Infection: A Real-Life Study. Front Pharmacol 2021;12:667584. [PMID: 33995097 DOI: 10.3389/fphar.2021.667584] [Reference Citation Analysis]
8 Kodama K, Fujisaki H, Kubota A, Kato H, Hirota K, Kuramochi H, Murota M, Tabata Y, Ueda M, Harada H, Kawahara T, Shinoda M, Watanabe N, Iida D, Terauchi H, Yasui S, Miyazawa S, Nagakawa J. E3710, a New Proton Pump Inhibitor, with a Long-Lasting Inhibitory Effect on Gastric Acid Secretion. J Pharmacol Exp Ther 2010;334:395-401. [DOI: 10.1124/jpet.110.167783] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]